IN THE NEWS - PATHFINDER Study: 4-Year Safety of Avapritinib for Patients with Advanced Systemic Mastocytosis

MD/alert

Suresh Balasubramanian, M.D., hematologist and medical oncologist, and member of the Hematology Oncology and Multiple Myeloma and Amyloidosis Multidisciplinary Teams at Karmanos, discussed the latest survival data from the PATHFINDER study, investigating the use of the targeted inhibitor KIT D816V. He explained how this therapy has transformed the treatment of systemic mastocytosis.

Watch the interview here (scroll down to view).

Suresh Balasubramanian, M.D.